Skip to main content

Table 2 Status of anticoagulant therapy among patients with NVAF at the different risk levels of stroke and bleeding

From: Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study

 NOAC, n(%)Warfarin, n(%)Aspirin, n(%)No medication, n(%)
CHA2DS2-VASc
 Male: 0~2; female: 0~118 (11.2)38 (23.6)37 (23.0)68 (42.2)
 Male ≥3; female ≥248 (11.1)107 (24.8)132 (30.5)145 (33.6)
HAS-BLED
  < 356 (10.5)131 (24.7)152 (28.6)192 (36.2)
  ≥ 310 (16.1)14 (22.6)17 (27.4)21 (33.9)
  1. Abbreviations: CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65–74 years, sex category (female), HAS-BLED Hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, NOAC Non-vitamin K antagonist oral anticoagulant, NVAF Non-valvular atrial fibrillation